Loading people...
Eugen Steiner is a Venture Partner at HealthCap based in Stockholm, Sweden, where he applies his medical expertise to invest in life sciences startups. He holds an MD and a PhD in Clinical Pharmacology from the Karolinska Institutet and has accumulated over 23 years of venture capital experience. Throughout his career, Steiner has served as the Chief Executive Officer for multiple portfolio companies, including Affibody, PyroSequencing, and Biostratum. During his tenure, HealthCap has backed 113 companies and achieved over 66 exits, contributing to the development of 22 approved drugs and 50 medical technology products that have generated $40 billion in accumulated sales. He frequently collaborates with firms such as AstraZeneca and Pharmacia to guide early-stage biotechnology enterprises toward operational independence. Steiner currently focuses on scaling European medical technology and pharmaceutical ventures by combining his clinical background with company-building expertise.
Eugen Steiner is a distinguished Venture Partner at HealthCap, a leading European venture capital firm renowned for its strategic investments in the life science sector. With a profound understanding of drug development and biotechnology, Eugen plays a pivotal role in identifying and nurturing promising companies that aim to address significant unmet medical needs.
At HealthCap, Eugen Steiner's responsibilities encompass deal sourcing, due diligence, and providing strategic guidance to portfolio companies. His investment focus is sharply honed on innovative pharmaceutical and biotechnology ventures. This includes companies developing novel therapeutics, advanced diagnostics, and medical technologies that have the potential to transform patient care and generate substantial value. His involvement helps steer these companies through critical development stages, from preclinical research to clinical trials and market entry.
Eugen's career background is marked by significant leadership positions within the life science industry. Prior to his role at HealthCap, he held executive positions at several prominent biotech firms, including serving as CEO of Karolinska Development and CEO of Nuevolution. These roles provided him with invaluable hands-on experience in building and scaling biotech companies, managing complex drug development programs, and navigating the regulatory landscape. His deep operational expertise is a significant asset to HealthCap's portfolio companies, offering them practical insights and strategic direction beyond just capital infusion.
Throughout his career, Eugen Steiner has been instrumental in the advancement of numerous innovative projects and companies. While specific individual investments as a Venture Partner are often part of a broader firm strategy, his contributions have undoubtedly supported HealthCap's track record of backing successful life science enterprises. His work has contributed to bringing novel therapies closer to patients, reflecting his commitment to scientific innovation and healthcare improvement. His expertise spans across various therapeutic areas, with a particular emphasis on oncology, immunology, and rare diseases, aligning perfectly with HealthCap's mission to invest in cutting-edge science with global impact.
Eugen Steiner's strategic vision and operational acumen make him a key figure in the European life science investment landscape, driving forward the next generation of medical breakthroughs.
Eugen Steiner is a Venture Partner at HealthCap, a leading European venture capital firm specializing in life sciences. He is known for his extensive background in drug development and biotechnology leadership.
Eugen Steiner primarily invests in innovative pharmaceutical and biotechnology companies. His focus areas include novel therapeutics, advanced diagnostics, and medical technologies, often within oncology, immunology, and rare diseases.
Eugen Steiner works as a Venture Partner at HealthCap, a prominent European venture capital firm dedicated to investing in the life science sector.
